← Back to Screener
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Price$11.49
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-4.13%
Price vs S&P 500 (4W)-20.91%
VGM Score57.00
Market Capitalization$429.57M
All Metrics
Book Value / Share (Quarterly)$6.69
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.54
Price vs S&P 500 (YTD)-7.63%
EPS (TTM)$-1.95
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-1.95
EPS (Annual)$-2.17
ROI (Annual)-22.98%
Cash / Share (Quarterly)$6.59
ROA (Last FY)-21.68%
EBITD / Share (TTM)$-2.18
ROE (5Y Avg)-26.99%
Cash Flow / Share (Annual)$-1.49
P/B Ratio1.72x
P/B Ratio (Quarterly)1.95x
Net Income / Employee (Annual)$-1,176,000
Net Interest Coverage (TTM)-112.73x
ROA (TTM)-25.64%
EPS Incl Extra (Annual)$-2.17
Current Ratio (Annual)27.50x
Quick Ratio (Quarterly)37.00x
3-Month Avg Trading Volume0.26M
52-Week Price Return176.87%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)8.59x
Asset Turnover (Annual)0.38x
52-Week High$16.33
EPS Excl Extra (Annual)$-2.17
26-Week Price Return3.79%
Quick Ratio (Annual)26.98x
13-Week Price Return-16.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)38.00x
Enterprise Value$409.41M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)46.34%
Cash / Share (Annual)$7.04
3-Month Return Std Dev63.54%
Net Income / Employee (TTM)$-1,146,000
ROE (Last FY)-22.98%
EPS Basic Excl Extra (Annual)$-2.17
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.95
ROI (TTM)-27.09%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)152.50%
Year-to-Date Return0.52%
5-Day Price Return-12.22%
EPS Normalized (Annual)$-2.17
ROA (5Y Avg)-22.63%
Net Profit Margin (Annual)45.44%
Month-to-Date Return-14.83%
EBITD / Share (Annual)$-2.45
Operating Margin (Annual)32.15%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-25.17%
EPS Basic Excl Extra (TTM)$-1.95
P/B Ratio (Annual)1.60x
Book Value / Share (Annual)$6.99
Price vs S&P 500 (13W)-25.05%
Beta0.22x
P/FCF (Annual)22.69x
Revenue / Share (TTM)$0.00
ROE (TTM)-27.09%
52-Week Low$3.57
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.39est. -0.54
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTNMContineum Therapeutics, Inc. Class A Common Stock | — | — | C | $11.49 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for serious diseases with high unmet need. The company's pipeline includes PIPE-791, a brain-penetrant LPA1 receptor inhibitor in development for idiopathic pulmonary fibrosis, and PIPE-307, a muscarinic M1 receptor inhibitor for depression and relapsing-remitting multiple sclerosis.